SH2D1B (SH2 Domain Containing 1B)

Notably, the model retained high accuracy in early-stage CRC (Stage I-II: AUC 0.929, 95% CI 0.868-0.989). Overall, this study provides a robust analytic framework for reproducible whole-blood RNA biomarker discovery and establishes a multi-gene signature with promising translational potential for minimally invasive and early CRC detection.

In summary, our findings uncover an important mechanism of ZNF683 NK cell exhaustion and suggest that transcriptional suppressor ZNF683 as a potential useful therapeutic target in immunotherapy of MM.

Our research identified a cluster of ZNF683+ NK cells with exhaustive phenotypes and impaired cytotoxicity in MM patients. We further confirmed that ZNF683 overexpression significantly downregulated SH2D1B expression via directly binding to its promoter in NK cells, thus leading to decreased cytotoxicity and impaired immunosurveillance of NK cells.

The described epigenetic signature could also provide new targets for more specific therapies for the disorder. Unstoppable campaign of Josep Carreras Leukaemia Foundation, Fundació La Marató de TV3, Cellex Foundation and CERCA Programme/Generalitat de Catalunya.

High-level co-expression of SLAMF7 and SH2D1B was significantly associated with better survival of the high-risk neuroblastoma patients. Together, this study supports the hypothesis that macrophages are important effector cells in the anti-high-risk neuroblastoma immunity, that PD-1 blockade therapy can be beneficial to the high-risk neuroblastoma subset with the PD-1/PD-L1 expression ratio >1, and that SLAMF7 is a new therapeutic target of high-risk neuroblastoma.

We performed a pretreatment immune-related gene expression analysis to predict outcomes of patients with advanced stage NSCLC receiving pembrolizumab as first-line therapy. Pretreatment tissue samples from 48 metastatic NSCLC patients with PD-L1 high expression (> 50% 22C3 clone testing antibody), who undergone first line pembrolizumab therapy, were evaluated... Our results support the hypothesis that pretreatment immune-related mRNA expression patterns, identified through the nCounter platform, may predict OS of patients with metastatic NSCLC treated with first line anti PD-1 therapy.